[SCHEDULE 13G] Immunic, Inc. SEC Filing
683 Capital Management, LLC, 683 Capital Partners, LP and Ari Zweiman (collectively the Reporting Persons) report beneficial ownership of warrants exercisable into 10,634,446 shares of Immunic, Inc. common stock. Those exercisable warrants, as disclosed, represent approximately 9.9% of the company's common stock on a diluted basis as presented in the filing. The reported position reflects shared voting and shared dispositive power over the warrants rather than sole control.
The percentage is calculated using the issuer's disclosed outstanding share base together with the maximum shares issuable upon exercise, and the warrants include a 9.99% beneficial ownership limitation that caps potential holdings.
683 Capital Management, LLC, 683 Capital Partners, LP e Ari Zweiman (congiuntamente le Persone segnalanti) dichiarano la propriet脿 beneficiaria di warrant esercitabili in 10.634.446 azioni ordinarie di Immunic, Inc. Tali warrant esercitabili, come indicato, rappresentano circa il 9,9% del capitale ordinario della societ脿 su base diluita, come riportato nella comunicazione. La posizione notificata riflette il potere di voto condiviso e il potere di disposizione condiviso sui warrant, e non il controllo esclusivo.
La percentuale 猫 calcolata utilizzando la base di azioni in circolazione divulgata dall'emittente insieme al massimo numero di azioni emettibili in caso di esercizio, e i warrant prevedono una limitazione della propriet脿 beneficiaria del 9,99% che pone un limite alle partecipazioni potenziali.
683 Capital Management, LLC, 683 Capital Partners, LP y Ari Zweiman (colectivamente, las Personas informantes) comunican la propiedad beneficiaria de warrants ejercitables en 10.634.446 acciones ordinarias de Immunic, Inc. Esos warrants ejercitables, seg煤n se indica, representan aproximadamente el 9,9% del capital social de la compa帽铆a en base diluida, tal como consta en la presentaci贸n. La posici贸n informada refleja el voto compartido y el poder de disposici贸n compartido sobre los warrants, en lugar de control exclusivo.
El porcentaje se calcula usando la base de acciones en circulaci贸n divulgada por el emisor junto con el m谩ximo de acciones susceptibles de emitirse por ejercicio, y los warrants incluyen una limitaci贸n de propiedad beneficiaria del 9,99% que fija un tope a las participaciones potenciales.
683 Capital Management, LLC, 683 Capital Partners, LP 氚� Ari Zweiman(齑濎弓頃橃棳 氤搓碃鞚�)鞚� Immunic, Inc. 氤错喌欤� 10,634,446欤茧 鞝勴櫂 臧�電ロ暅 鞗岆煱韸胳棎 雽�頃� 靾橃澋鞝� 靻岇湢毳� 鞁犼碃頃╇媹雼�. 瓿店皽霅� 氚旍棎 霐半ゴ氅� 頃措嫻 頄夓偓 臧�電ロ暅 鞗岆煱韸鸽姅 鞝滌稖霅� 鞁犼碃靹� 旮办鞙茧 須岇偓鞚� 氤错喌欤茧ゼ 頋劃 旮办鞙茧 鞎� 9.9%毳� 彀頃╇媹雼�. 氤搓碃霅� 歆�攵勳潃 鞗岆煱韸胳棎 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 瓿惦彊 觳橂秳 甓岉暅鞚� 氚橃榿頃橂┌ 雼弲 韱奠牅電� 鞎勲嫏雼堧嫟.
氚彪秳鞙潃 氚滍枆鞚胳澊 瓿店皽頃� 鞙犿喌 欤检嫕靾橃棎 頄夓偓 鞁� 氚滍枆霅� 斓滊寑 欤检嫕鞚� 頃╈偘頃橃棳 瓿勳偘霅橂┌, 頃措嫻 鞗岆煱韸胳棎電� 鞛犾灛鞝� 氤挫湢毳� 鞝滍暅頃橂姅 9.99%鞚� 靾橃澋鞝� 靻岇湢 頃滊弰臧� 韽暔霅橃柎 鞛堨姷雼堧嫟.
683 Capital Management, LLC, 683 Capital Partners, LP et Ari Zweiman (collectivement les personnes d茅clarante) d茅clarent la propri茅t茅 b茅n茅ficiaire de warrants exer莽ables en 10.634.446 actions ordinaires d'Immunic, Inc. Ces warrants exer莽ables repr茅sentent, comme indiqu茅, environ 9,9% du capital social de la soci茅t茅 sur une base dilu茅e, selon le d茅p么t. La position d茅clar茅e refl猫te le droit de vote partag茅 et le pouvoir discr茅tionnaire partag茅 sur les warrants plut么t qu'un contr么le exclusif.
Le pourcentage est calcul茅 en utilisant la base d'actions en circulation divulgu茅e par l'茅metteur ainsi que le nombre maximal d'actions pouvant 锚tre 茅mises 脿 l'exercice, et les warrants comprennent une limitation de propri茅t茅 b茅n茅ficiaire de 9,99% qui plafonne les participations potentielles.
683 Capital Management, LLC, 683 Capital Partners, LP und Ari Zweiman (zusammen die meldenden Personen) melden wirtschaftliches Eigentum an Warrants, die in 10.634.446 Stammaktien von Immunic, Inc. aus眉bbar sind. Diese aus眉bbaren Warrants stellen, wie angegeben, etwa 9,9% des Stammkapitals der Gesellschaft auf verw盲sserter Basis dar, wie in der Meldung dargestellt. Die gemeldete Position spiegelt geteilte Stimmrechte und geteilte Verf眉gungsbefugnis 眉ber die Warrants wider und nicht die alleinige Kontrolle.
Der Prozentsatz wird anhand der vom Emittenten offengelegten ausstehenden Aktienbasis zusammen mit der maximalen Anzahl bei Aus眉bung auszugebender Aktien berechnet, und die Warrants beinhalten eine Beschr盲nkung der wirtschaftlichen Eigent眉merschaft von 9,99%, die die potenziellen Best盲nde begrenzt.
- Exercisable warrants equal 10,634,446 shares, a clearly disclosed, quantifiable economic interest
- Declared ownership capped at ~9.9%, providing transparency about maximum potential dilution from these warrants
- Reporting Persons hold only shared voting and shared dispositive power, not sole control over the securities
- Warrants include a 9.99% ownership limitation, which prevents acquiring a larger ownership stake through these instruments
Insights
TL;DR: Reporting Persons hold exercisable warrants for 10.63M shares, about 9.9% diluted鈥攎aterial but below control thresholds.
The filing discloses exercisable warrants to purchase 10,634,446 shares, which the Reporting Persons may be deemed to beneficially own on a diluted basis. That position equals roughly 9.9% of the company when using the issuer's disclosed outstanding share count plus the warrants. The holdings are structured as shared voting and dispositive power and are subject to a 9.99% ownership cap written into the warrants, limiting further aggregation above that threshold.
TL;DR: Significant minority economic exposure disclosed via warrants with shared voting/dispositive authority and an explicit ownership limit.
The schedule reports that 683 Capital Partners holds exercisable warrants convertible into 10,634,446 shares, with 683 Capital Management and Ari Zweiman potentially deemed to have beneficial ownership through management and control relationships. The filing explicitly notes shared voting and dispositive powers rather than sole control and references a contractual 9.99% beneficial ownership limitation in each warrant, which is relevant to governance and potential future aggregation of stakes.
683 Capital Management, LLC, 683 Capital Partners, LP e Ari Zweiman (congiuntamente le Persone segnalanti) dichiarano la propriet脿 beneficiaria di warrant esercitabili in 10.634.446 azioni ordinarie di Immunic, Inc. Tali warrant esercitabili, come indicato, rappresentano circa il 9,9% del capitale ordinario della societ脿 su base diluita, come riportato nella comunicazione. La posizione notificata riflette il potere di voto condiviso e il potere di disposizione condiviso sui warrant, e non il controllo esclusivo.
La percentuale 猫 calcolata utilizzando la base di azioni in circolazione divulgata dall'emittente insieme al massimo numero di azioni emettibili in caso di esercizio, e i warrant prevedono una limitazione della propriet脿 beneficiaria del 9,99% che pone un limite alle partecipazioni potenziali.
683 Capital Management, LLC, 683 Capital Partners, LP y Ari Zweiman (colectivamente, las Personas informantes) comunican la propiedad beneficiaria de warrants ejercitables en 10.634.446 acciones ordinarias de Immunic, Inc. Esos warrants ejercitables, seg煤n se indica, representan aproximadamente el 9,9% del capital social de la compa帽铆a en base diluida, tal como consta en la presentaci贸n. La posici贸n informada refleja el voto compartido y el poder de disposici贸n compartido sobre los warrants, en lugar de control exclusivo.
El porcentaje se calcula usando la base de acciones en circulaci贸n divulgada por el emisor junto con el m谩ximo de acciones susceptibles de emitirse por ejercicio, y los warrants incluyen una limitaci贸n de propiedad beneficiaria del 9,99% que fija un tope a las participaciones potenciales.
683 Capital Management, LLC, 683 Capital Partners, LP 氚� Ari Zweiman(齑濎弓頃橃棳 氤搓碃鞚�)鞚� Immunic, Inc. 氤错喌欤� 10,634,446欤茧 鞝勴櫂 臧�電ロ暅 鞗岆煱韸胳棎 雽�頃� 靾橃澋鞝� 靻岇湢毳� 鞁犼碃頃╇媹雼�. 瓿店皽霅� 氚旍棎 霐半ゴ氅� 頃措嫻 頄夓偓 臧�電ロ暅 鞗岆煱韸鸽姅 鞝滌稖霅� 鞁犼碃靹� 旮办鞙茧 須岇偓鞚� 氤错喌欤茧ゼ 頋劃 旮办鞙茧 鞎� 9.9%毳� 彀頃╇媹雼�. 氤搓碃霅� 歆�攵勳潃 鞗岆煱韸胳棎 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 瓿惦彊 觳橂秳 甓岉暅鞚� 氚橃榿頃橂┌ 雼弲 韱奠牅電� 鞎勲嫏雼堧嫟.
氚彪秳鞙潃 氚滍枆鞚胳澊 瓿店皽頃� 鞙犿喌 欤检嫕靾橃棎 頄夓偓 鞁� 氚滍枆霅� 斓滊寑 欤检嫕鞚� 頃╈偘頃橃棳 瓿勳偘霅橂┌, 頃措嫻 鞗岆煱韸胳棎電� 鞛犾灛鞝� 氤挫湢毳� 鞝滍暅頃橂姅 9.99%鞚� 靾橃澋鞝� 靻岇湢 頃滊弰臧� 韽暔霅橃柎 鞛堨姷雼堧嫟.
683 Capital Management, LLC, 683 Capital Partners, LP et Ari Zweiman (collectivement les personnes d茅clarante) d茅clarent la propri茅t茅 b茅n茅ficiaire de warrants exer莽ables en 10.634.446 actions ordinaires d'Immunic, Inc. Ces warrants exer莽ables repr茅sentent, comme indiqu茅, environ 9,9% du capital social de la soci茅t茅 sur une base dilu茅e, selon le d茅p么t. La position d茅clar茅e refl猫te le droit de vote partag茅 et le pouvoir discr茅tionnaire partag茅 sur les warrants plut么t qu'un contr么le exclusif.
Le pourcentage est calcul茅 en utilisant la base d'actions en circulation divulgu茅e par l'茅metteur ainsi que le nombre maximal d'actions pouvant 锚tre 茅mises 脿 l'exercice, et les warrants comprennent une limitation de propri茅t茅 b茅n茅ficiaire de 9,99% qui plafonne les participations potentielles.
683 Capital Management, LLC, 683 Capital Partners, LP und Ari Zweiman (zusammen die meldenden Personen) melden wirtschaftliches Eigentum an Warrants, die in 10.634.446 Stammaktien von Immunic, Inc. aus眉bbar sind. Diese aus眉bbaren Warrants stellen, wie angegeben, etwa 9,9% des Stammkapitals der Gesellschaft auf verw盲sserter Basis dar, wie in der Meldung dargestellt. Die gemeldete Position spiegelt geteilte Stimmrechte und geteilte Verf眉gungsbefugnis 眉ber die Warrants wider und nicht die alleinige Kontrolle.
Der Prozentsatz wird anhand der vom Emittenten offengelegten ausstehenden Aktienbasis zusammen mit der maximalen Anzahl bei Aus眉bung auszugebender Aktien berechnet, und die Warrants beinhalten eine Beschr盲nkung der wirtschaftlichen Eigent眉merschaft von 9,99%, die die potenziellen Best盲nde begrenzt.
FAQ
What stake does 683 Capital report in Immunic (IMUX)?
Are the reported securities shares or warrants for IMUX?
Does 683 Capital have sole voting control over the IMUX securities?
How was the ~9.9% ownership percentage calculated for IMUX?
Who are the Reporting Persons named in the Schedule 13G for IMUX?
